We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
Read MoreHide Full Article
Precigen, Inc. (PGEN - Free Report) announced that the FDA granted Fast Track designation to its early-stage candidate, PRGN-3006 UltraCAR-T, for treating patients with relapsed or refractory (r/r) acute myeloid leukemia (“AML”).
The FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions.
A phase I study is currently evaluating the candidate in adult patients with r/r AML.
Precigen’s PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (“CAR”) T cell therapy candidate that targets CD33, an antigen, which is over-expressed on AML blasts. The candidate simultaneously enhances in vivo expansion and persistence by generating membrane-bound IL-15. The candidate also has a kill switch to eliminate CAR-T cells conditionally for an improved safety profile. The company uses its non-viral Sleeping Beauty system and UltraCAR-T platform to develop this multigenic CAR T therapy.
The company stated that its UltraCAR-T platform helps to design CAR T therapies, which have the potential to overcome limitations of currently available CAR-T therapies, including exhausted phenotype of T cells resulting from lengthy ex vivo expansion.
The company’s PRGN-3006 UltraCAR-T was granted Orphan Drug designation by the FDA in 2020.
Precigen’s shares rose 11.5% on Apr 4, following the Fast Track status. However, the stock has declined 31.8% so far this year in comparison with the industry’s 11.9% decrease.
Image Source: Zacks Investment Research
Precigen is focused on developing the next generation of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company is developing six pipeline candidates, apart from PRGN-3006 UltraCAR-T, in early-stage clinical studies.
The candidates target different cancer indications including ovarian cancer and human papillomavirus-positive, rare diseases like myelodysplastic syndromes and type I diabetes mellitus. The targeted indications represent significant opportunities.
Although Precigen’s CAR T therapies hold potential, there are multiple FDA-approved CAR T therapies available currently targeting different oncology indications. These include bluebird bio (BLUE - Free Report) and Bristol-Myers’ (BMY - Free Report) Abecma, Gilead’s (GILD - Free Report) Yescarta and Novartis’ Kymriah.
Gilead and Novartis were one of the first companies to get FDA approval for a CAR T cell therapy in 2017. Gilead added Yescarta to its portfolio following the acquisition of Kite Pharma in the same year.
bluebird Bio and Bristol-Myers developed Abecma under a collaboration and received FDA approval for treating relapsed or refractory multiple myeloma last year. Abecma is the only approved CAR T therapy in bluebird Bio’s portfolio while Bristol-Myers has another commercialized CAR T therapy, Breyanzi, approved for treating r/r large B-cell lymphoma in 2021.
Image: Bigstock
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
Precigen, Inc. (PGEN - Free Report) announced that the FDA granted Fast Track designation to its early-stage candidate, PRGN-3006 UltraCAR-T, for treating patients with relapsed or refractory (r/r) acute myeloid leukemia (“AML”).
The FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions.
A phase I study is currently evaluating the candidate in adult patients with r/r AML.
Precigen’s PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (“CAR”) T cell therapy candidate that targets CD33, an antigen, which is over-expressed on AML blasts. The candidate simultaneously enhances in vivo expansion and persistence by generating membrane-bound IL-15. The candidate also has a kill switch to eliminate CAR-T cells conditionally for an improved safety profile. The company uses its non-viral Sleeping Beauty system and UltraCAR-T platform to develop this multigenic CAR T therapy.
The company stated that its UltraCAR-T platform helps to design CAR T therapies, which have the potential to overcome limitations of currently available CAR-T therapies, including exhausted phenotype of T cells resulting from lengthy ex vivo expansion.
The company’s PRGN-3006 UltraCAR-T was granted Orphan Drug designation by the FDA in 2020.
Precigen’s shares rose 11.5% on Apr 4, following the Fast Track status. However, the stock has declined 31.8% so far this year in comparison with the industry’s 11.9% decrease.
Image Source: Zacks Investment Research
Precigen is focused on developing the next generation of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company is developing six pipeline candidates, apart from PRGN-3006 UltraCAR-T, in early-stage clinical studies.
The candidates target different cancer indications including ovarian cancer and human papillomavirus-positive, rare diseases like myelodysplastic syndromes and type I diabetes mellitus. The targeted indications represent significant opportunities.
Although Precigen’s CAR T therapies hold potential, there are multiple FDA-approved CAR T therapies available currently targeting different oncology indications. These include bluebird bio (BLUE - Free Report) and Bristol-Myers’ (BMY - Free Report) Abecma, Gilead’s (GILD - Free Report) Yescarta and Novartis’ Kymriah.
Gilead and Novartis were one of the first companies to get FDA approval for a CAR T cell therapy in 2017. Gilead added Yescarta to its portfolio following the acquisition of Kite Pharma in the same year.
bluebird Bio and Bristol-Myers developed Abecma under a collaboration and received FDA approval for treating relapsed or refractory multiple myeloma last year. Abecma is the only approved CAR T therapy in bluebird Bio’s portfolio while Bristol-Myers has another commercialized CAR T therapy, Breyanzi, approved for treating r/r large B-cell lymphoma in 2021.
Precigen, Inc. Price
Precigen, Inc. price | Precigen, Inc. Quote
Zacks Rank
Precigen presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.